title: Effect of infusing rat monoclonal antibodies to the murine GPIb-IX-V complex on platelet and megakaryocyte morphology in mice.
abstract: In the Bernard-Soulier syndrome, the absence of GPIb-IX-V leads to thrombocytopenia and giant platelets. In autoimmune thrombocytopenia in man, anti-platelet antibodies are associated with changes in megakaryocyte (MK) morphology and platelet size heterogeneity. We have compared the ultrastructural changes in mature MK following the infusion of rat monoclonal antibodies (MoAbs) to different epitopes of the murine GPIb-IX-V complex in mice. Blood and marrow samples were examined during both the acute thrombocytopenic phase and during the recovery phase. A MoAb to GPV induced neither thrombocytopenia nor changes in platelet morphology. During the acute thrombocytopenic phase with anti-GPIbalpha MoAbs, the size of residual platelets was heterogeneous and included large forms and platelets with few granules. During recovery, platelet size heterogeneity continued, and some platelets showed signs of activation. But only rare platelets were giant forms with ultrastructural defects resembling BSS. Megakaryocytopoiesis during acute thrombocytopenia was already abnormal, with some mature cells often showing vacuoles and an irregular development of the demarcation membrane system which varied in extent. These changes continued into the recovery phase. The anti-GPV MoAb had no effect on MK. Thus, anti-platelet antibodies can induce a different medullary response even when binding to the same receptor.
authors.affiliation: UMR 5533 CNRS, Hôpital Cardiologique, Pessac, France.
authors.forename: Christel
authors.initials: C
authors.lastname: Poujol
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Bergmeier
authors.forename: Paquita
authors.initials: P
authors.lastname: Nurden
authors.forename: Bernard
authors.initials: B
authors.lastname: Nieswandt
authors.forename: Alan
authors.initials: A
authors.lastname: Nurden
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D001773:Blood Cells; D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects; D001854:Bone Marrow Cells; D048429:Cell Size / Q000187:drug effects; D005165:Factor V / Q000276:immunology; D007275:Injections, Intravenous; D008533:Megakaryocytes / Q000166:cytology* / Q000187:drug effects; D051379:Mice; D008854:Microscopy, Electron; D010976:Platelet Count; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000276:immunology*; D051381:Rats
chemical_list: D000911:Antibodies, Monoclonal; D019038:Platelet Glycoprotein GPIb-IX Complex; D005165:Factor V